Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine in C57BL/6 mice

Neuroscience Letters

Volumn 281, Issue 2-3, 2000, Pages 167-170

  Zou, Ling Long ^a   Xu, Jing ^a   Jankovic, Joseph ^a   He, Yi ^a   Appel, Stanley H ^a   Le, Wei Dong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine; Lipid peroxidation; Neuroprotection; Parkinson's disease; Pramipexole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; FREE RADICAL; LIPID; PRAMIPEXOLE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENZOTHIAZOLES; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; FREE RADICAL SCAVENGERS; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; SUBSTANTIA NIGRA; THIAZOLES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TYROSINE 3-MONOOXYGENASE;

EID: 0033993476     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)00853-3     Document Type: Article

References (20)

1. Cassarino D.S., Fall C.P., Smith T.S., Bennett J.P. Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71:1998;295-301.
2. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 114:1991;1953-1975.
3. Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann. NY. Acad. Sci. 570:1989;186-196.
4. Gomez-Vargas M., Nishibayashi-Asanuma S., Asanuma M., Kondo Y., Iwata E., Ogawa N. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 790:1998;202-208.
5. Hall E.D., Andrus P.K., Oostveen J.A., Althaus J.S., Von Voigtlander P.F. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742:1996;80-88.
6. Jankovic J., Marsden C.D. Therapeutic strategies in Parkinson's disease. Jankovic J., Tolosa E. Parkinson's Disease and Movement Disorders, 3rd edn. 1998;67-104 Williams and Wilkins, Baltimore MD.
7. 3H-GBR12935 to measure dopaminergic nerve terminal growth into rat striatum. Dev. Brain Res. 67:1992;375-377.
8. Nelson E.L., Liang C.L., Sinton C.M., German D.C. Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369:1996;361-371.
9. Ogawa N., Edamatsu R., Mizukawa K., Asanuma M., Kohno M., Mori A. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv. Neurol. 60:1993;242-250.
10. Ogawa N., Tanaka K., Asanuma M., Kawai M., Masumizu T., Kohno M., Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657:1994;207-213.
11. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:1979;351-358.
12. Olanow C.W., Jenner P., Broks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44:1998;S167-S174.
13. Pakkenberg B., Moller A., Gundersen H.J., Mouritzen D.A., Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry. 54:1991;30-33.
14. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 13:1998;35-38.
15. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
16. Sethy V.H., Wu H., Oostveen J.A., Hall E.D. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 754:1997;181-186.
17. Sriram K., Pai K.S., Boyd M.R., Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749:1997;44-52.
18. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154:1999;1423-1429.
19. Zou L., Jankovic J., Rowe D.B., Xie W., Appel S.H., Le W. Neuroprotection by pramipexole against dopa- and levodopa-induced cytotoxicity. Life Sci. 64:1999;1275-1285.
20. Yamamoto M. Do dopamine agonists provide neuroprotection. Neurology. 51:1998;S10-S12.